biopharma
Coverage of biopharma in the Nexus archive.
- STAT+: Kalshi comes for biopharma, with prediction markets for clinical trials and FDA approvals
Kalshi, a major prediction market exchange, will launch markets for betting on clinical trials and FDA approvals in collaboration with tech partner AppliedXL. The initiative expands prediction markets into the biopharma industry, focusing on clinical trial outcomes and regulatory decisions.
- STAT+: A former AI regulator, now in industry, says biopharma is reading FDA’s guidance wrong
Tala Fakhouri, who previously worked at the FDA on AI policy, now at Parexel, criticizes the biopharma industry for misinterpreting the FDA's flexible guidance in conservative ways to avoid risk. The article highlights concerns about how industry implementation diverges from the FDA's intended approach.
- Novo-Backed Drugmaker Avalyn Soars 44% After $300 Million US IPO
Avalyn Pharma Inc., a biopharma company developing inhaled treatments for rare lung diseases, raised $300 million in a US initial public offering that priced at the top of its marketed range. The stock surged 44% on its first day of trading, with CEO Lyn Baranowski ringing the opening bell at Nasdaq MarketSite in New York.